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Aggressive ﬁbromatosis (AF) or desmoid tumor is a rare condition, characterized by deep tissue invasion by a monoclonal
ﬁbroblastic neoplasm, developed from musculoaponeurotic structures. Surgery is the treatment of choice, but negative margins
canhardlybeenachievedinlargetumors,andcanleadtomajorfunctionaldisability.AFmedicaltherapyincludesnonsteroidsanti-
inﬂammatory drugs, tamoxifen, with inconsistent results. Several reports of imatinib eﬃcacy in AF appear in the literature. Here,
wedescribefortheﬁrsttimeaV530IKIT exon10mutantthatwasassociatedtoadramaticimatinibresponseinanextraabdominal
aggressive ﬁbromatosis. The previously discovered V530I substitution was characterized in the core binding factor AML, but had
never been reported in any other condition, so far. In this paper, we discuss the KIT exon 10 mutations or polymorphisms that
have been described in a variety of KIT-related conditions, including acute myelogenous leukemia, mastocytosis, and aggressive
ﬁbromatosis.
1.CaseReport
A 22-year-old Caucasian female without any particular
medical history suﬀered from a traumatic fracture of the
left humerus great tuberosity in 2002. She underwent a
non-operative treatment with a Mayo-Clinic splint and was
discharged from the hospital. Radiologic outcome was unre-
markable, though she complained with persistent shoulder
pain. Three years later, a painful mass of the shoulder rapidly
appeared, impairing shoulder mobility. She was referred to
our institution. Clinical examination revealed a hard, bulky
mass of the shoulder, with collateral circulation. The tumor
involved the whole curving contour of the shoulder, and
reached the axilla at its posterior limit. Mobilization of the
arm was almost impossible due to both pain and stiﬀness
(Figure 1(a)). A shoulder MRI revealed a 12×6cm irregular,
heterogeneous mass of the posterior part of the shoulder
(Figure 1(b)). The tumor invaded subcutaneous tissue as
well as the deltoid and infrasupinatous muscles. Necrotic
areasdiagnosedasT1-hyposignalwerefound,aswellasother
tumor areas that were strongly enhanced by contrast injec-
tion. There was no apparent bone destruction. A surgical
biopsy was performed, diagnosing aggressive ﬁbromatosis
(extraabdominal desmoids tumor).
Due to the tumor burden, curative surgery could not
be performed, and a medical therapy consisting in imatinib
mesylate (Glivec) was started at a daily dose of 400mg. After
4 weeks of treatment, the patient noticed an improvement
in the abduction of the arm as well as a slight tumor size
decrease. The treatment was continued at the same dosing,
with consistent improvement in mobility, tumor measure-
ments and analgesics consumption. There was no signiﬁcant
side-eﬀects. The treatment was ﬁnally stopped at month
34, in the setting of tumor regression, complete recovery2 Sarcoma
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Figure 1: Clinical ﬁndings at diagnosis. Note the bulky mass of the shoulder with collateral circulation (a). MRI (T1 gadolinium sequences)
shows a heterogeneous tumor inﬁltrating muscles and subcutaneous tissue (b).
(a) (b)
Figure 2: Clinical response after Imatinib therapy: Recovery of the whole curving contour of the shoulder, with decrease of collateral
circulation (a). MRI ﬁndings: T1 gadolinium sequences conﬁrming the tumor very good partial response with disappearance of tumor-
related hypersignal (b).
of arm mobility and function and complete discontinuation
of analgesics (Figure 2(a)). Control MRI of the shoulder
conﬁrmed the very good partial response (Figure 2(b)). At
a follow-up of 42 months (1 year oﬀ-therapy), the patient
remains tumor and symptoms-free, without any tumor re-
growth.
In the light of such a dramatic response to ima-
tinib, c-kit exon 10 was fully sequenced from the tumor
frozen samples. 50ng of genomic DNA was ampliﬁed by
PCR in 50µl reaction volume containing 2,5U AmpliTaq
Gold DNA polymerase (Applied Biosystems, Forster city,
CA), 0,2mMdNTP, 1,5mMMgCl2,a n d0 , 2µm of the for-
ward and reverse primers 5 -ATCCCATCCTGCCAAAGTT-
3  and 5 -CTGTGGGGAGAAAGGGAAA-3 ,r e s p e c t i v e l y ,
ﬂanking exon 10. PCR products were veriﬁed by elec-
trophoresis, showing a 246bp ampliﬁed fragment, puriﬁed
byusingMicrocon-PCRFilterUnit(Millipore,Paris,France)
and directly sequenced with the Big Dye Terminator v1.1
Cycle sequencing kit (Applied Biosystems, Forster city, CA).
ﬁnally the PCR product was analyzed on ABI PRISM 3100
Genetic Analyser (Applied Biosystems, Forster city, CA). The
sequences were aligned with the GB sequence of human
CKIT (locus HSU63834) using the software Seqscape v2.5
(Applied Biosystems, Forster city, CA). All sequencing reac-
tions wereperformedinboth forwardandreversedirections,
and the mutation was conﬁrmed by a second sequencing
on an independent PCR, revealing a V530I mutation in the
transmembrane domain of c-kit (Figure 3).
2. Discussion
Aggressive ﬁbromatosis (AF) is a monoclonal disease, arising
from deep musculoaponeurotic structures [1]. In spite of
being nonmalignant, the outcome of AF is characterized
by local aggressiveness, making curative surgery a diﬃcultSarcoma 3
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Figure 3: KIT exon 10 point mutation 1609 G→A (resulting in the
amino-acid substitution V530I).
challenge, as patients are exposed to local recurrence. The
clinical outcome of AF is unpredictable, and many treatment
options have been considered, including surgery, radiation
therapy and medical therapy. Systemic medical therapy has
focused on NSAIDs such as Sulindac and anti-Cox2 as well
as hormonal therapy (tamoxifen) although AF inconsistently
express estrogen receptors [2].
The KIT gene encodes the stem cell growth factor
receptor, a type III transmembrane receptor tyrosine kinase
that has been involved in the pathogenesis of various con-
ditions, including gastro-intestinal stromal tumors (GISTs),
mastocytosis, acute myelogenous leukemia (AML) as well
as piebaldism, a rare autosomal inherited skin disorder.
The tyrosine kinase inhibitor imatinib mesylate (Glivec)
has become a cornerstone of advanced GIST, in which KIT
exon 11 mutations are associated with imatinib eﬃcacy, as
opposedtothesethatarepresentinexon9[3].However,KIT
exon 10 mutations have not been reported so far in GISTs, as
opposed to deletions at the intron10-exon11 boundary that
may impact response to imatinib [4].
Imatinib has been incorporated in the therapeutic arma-
mentarium of AF, in the light of several case reports of long-
lasting responses [5–8]. However, all AF do not respond to
imatinib treatment, as shown in a retrospective analysis of 19
casesofheavilypretreatedpatientsinwhomtheresponserate
was only 15.7% (3/19PR) [8]. Interestingly, it is unlikely that
positive KIT staining would predict imatinib sensitivity as in
this series, most of the cases were KIT negative. Molecular
determinants of tumor response to tyrosine kinase inhibitors
are well known in gastro-intestinal stromal tumors, where
KIT mutations are predictive for imatinib eﬃcacy [3]. In
the retrospective series reported by Heinrich et al., no KIT
mutation was however found, even in the three responders
to imatinib [8]. This data contrasts with previous reports
of KIT exon 10 point mutation 1621 A→C (resulting
in the amino-acid substitution M541L) that could predict
imatinib sensitivity [6]. Similar ﬁndings were reported in a
French Sarcoma Group study, where 3 out of 10 patients
experiencing tumor control with imatinib actually had an
M541L mutation [9]. Moreover, Seinfeld et al. reported the
occurrence of a limited clinical response, again in a M541L
patient [10]. However, contradictory data also appear in
the literature. In the light of experiments conducted by
Tamborini et al., as well as Bertucci et al., it was hypothesized
that the exon 10 M541L variant is not activating neither
inactivating and is actually a KIT polymorphism [11, 12].
Consistent ﬁndings were reported by Kr¨ uger et al., who
found that the allele frequency of the KIT variant M541L
was as high as 8.1% in the healthy population, not diﬀering
from chronic myelogenous patients (8.3%) [13]. The V530I
variant has to our knowledge, never been described so far, in
either AF or other KIT-related diseases such as mastocytosis,
GISTs or piebaldism, [14, 15]. The exon 10 V530I substi-
tution alters the transmembrane domain of KIT (contained
between amino acids 521–543), and was described in acute
myelogenous leukemia [16, 17]. Similar and rare (<5%)
exon 10 KIT-activating transmembrane mutations such as
A533D or F522C have been reported in mastocytosis [15].
KIT deletions or insertions appear in 7 to 17% of AML
cases (raising to 33% in the setting of chromosome 16
inversion), aﬀecting members of the core binding factor
(CBF) gene family [16–18]. In a series of 103 AML patients,
those harboring a KIT mutation had a shorter event-free and
relapse-free survival [18]. There is little data with regard to
imatinib therapy in AML patients with CBF KIT mutations.
In a series of 3 patients, imatinib had transient activity
in a patient with exon 8 in-frame deletion, but none in
the 2 patients carrying D816Y and D816V mutations [19].
In a series of published by Cortes et al., 18 patients with
recurrent or refractory AML or myelodysplastic syndrome
were challenged with imatinib, with very transient results
[20]. Unfortunately, no KIT analysis was performed in this
study. A trial investigating dasatinib, another tyrosine kinase
inhibitor is currently recruiting AML patients harboring
CBF mutations in France. Interestingly, V530I variants
were associated, in this condition with a greater imatinib
sensitivity, as the IC50 was lower than the wild-type KIT
by a 5-fold factor. Moreover, inhibition of V530I variants
resulted in both proliferation abrogation and increased
apoptosisinvitro[16].Wehavenotinvestigatedwhetherour
patient exhibited a germline or a somatic mutation as tissue
samplingconsistedintumorbiopsyonly,andnoconsentwas
obtained to test for any germline mutation in our patient
who lacked signiﬁcant familial history of cancer. There is,
moreover, no data in the literature supporting the hypothesis
that the V530I KIT (as opposed to the aforementioned
M541L) mutation could be a polymorphism rather than a
rare, highly penetrating alteration.
Our patient exhibited a typical medical history of
trauma, preceding the onset of AF by an interval of three
years,adelayconsistentwithliteraturedata[2].Thereislittle
data in the literature regarding imatinib treatment duration
in AF. Of note, in our case, evidence for treatment eﬃcacy
was present as soon as 4 weeks after treatment started.
Moreover,imatinibwasadministeredfor3yearsasthetumor
size constantly decreased during this period. However, and
as opposed to the report by Wcislo et al., imatinib was
then stopped without subsequent local relapse [7]. In other
reports, the duration of imatinib therapy varied between 34
weeks and 16 months [5, 6, 10].4 Sarcoma
Based on the literature data, as well as this report, it
appears mandatory that AF patients be screened not only for
M541L substitution, which physiopathology remains at the
least, controversial, but should undergo systematic exon 10
sequencingtodetecttransmembranevariants,suchasV530I.
Hence, the presence of such a mutation could support front-
line imatinib therapy, rather than more classic strategies,
including tamoxifen or NSAIDs. Dramatic response to ima-
tinibisclearlyassociatedwiththissubstitution,andprovided
such a mutation has been detected, not only imatinib can be
considered, but also other TK inhibitors, such as sunitinib
or others [21]. Whether the V530I variant might successfully
be challenged with tyrosine kinase inhibitors other than
imatinib is unknown. Growney et al. tried to assess the
eﬃcacy of PKC412, a novel tyrosine kinase inhibitor in a
variety of KIT mutants, including V530I, but this variant
could not transform the Ba/F3 cells in their experiment
[21]. Interestingly, reports of sunitinib eﬃcacy in imatinib-
resistant AF patients appear in the literature, suggesting that
as in GISTs, treatment strategies with “rescue” alternate TK
inhibitors can be considered in selected patients [22].
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